JHVEPhoto
Shares of Biohaven (NYSE:BHVN) fell ~11% in the premarket on Thursday after the company said that the FDA has extended the review period of its marketing application for its lead drug troriluzole, targeted at spinocerebellar ataxia (SCA), a group of rare